Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.
| Revenue (Most Recent Fiscal Year) | $0.22M |
| Net Income (Most Recent Fiscal Year) | $-24.91M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.68 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4389.33% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -102.31% |
| Return on Assets (Trailing 12 Months) | -70.00% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.03 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.52M |
| Free Float | 16.42M |
| Market Capitalization | $12.74M |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.58% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |